MARKET

ALBO

ALBO

Albireo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.15
-0.50
-2.11%
After Hours: 23.15 0 0.00% 16:00 01/24 EST
OPEN
23.77
PREV CLOSE
23.65
HIGH
23.93
LOW
23.01
VOLUME
30.21K
TURNOVER
--
52 WEEK HIGH
38.69
52 WEEK LOW
16.13
MARKET CAP
293.69M
P/E (TTM)
-4.0011
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALBO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALBO News

  • Albireo Joins with Alagille Syndrome Community in Celebrating First International Awareness Day
  • GlobeNewswire.1d ago
  • Do Hedge Funds Love Albireo Pharma, Inc. (ALBO)?
  • Insider Monkey.12/20/2019 02:51
  • Biotech Stocks Are In a Position to Break Out in 2020, Analysts Say
  • Barrons.com.12/19/2019 14:17
  • Is Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Salary Justified?
  • Simply Wall St..12/17/2019 10:06

More

Industry

Biotechnology & Medical Research
-2.27%
Pharmaceuticals & Medical Research
-1.88%

Hot Stocks

Name
Price
%Change

About ALBO

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).
More

Webull offers Albireo Pharma Inc (ALBO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.